MCL1 and neoplasm: To target tumor metabolism, Elgendy et al. [81] proposed that the combination of intermittent fasting-induced hypoglycemia and metformin impairs tumor metabolic plasticity and growth via the PP2A-GSK3β-MCL-1 axis.